Abstract:Context Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with poor prognosis and high recurrence rates in patients. The development of MCL is largely attributed to cell cycle dysregulation. Cell division cycle 20 (CDC20) is a key member of cell cycle checkpoints, and high expression of CDC20 was reported in a variety of tumors. Few studies have explored the role of CDC20 in MCL. Objective This study was aimed to investigate whether CDC20 could promote cancer progression and the potential of CDC20 to be a therapeutic target in MCL. Design Peripheral blood mononuclear cells (PBMCs) from 18 MCL patients and 7 healthy donors and 5 MCL cell lines (Jeko, Mino, Rec1, Z138, and JVM2) were acquired to detect CDC20 expression. CDC20 inhibitor apcin was used in Z138 to evaluate its antitumor effects in vitro, including cell viability, cell apoptosis, cell cycle, cell migration, and invasion. Possible changes of some related genes were assessed after apcin treatment. Results CDC20 was overexpressed in 94.4% (17/18) of MCL patients and 5 MCL cell lines compared with healthy controls. Cell growth was inhibited, and cell apoptosis was induced in apcin-treated Z138 cells. After 48 h apcin treatment, cell cycle was arrested in the G2/M phase, characterized by an increased number of Z138 cells in this period. The abilities of cell migration and invasion were significantly attenuated with apcin treatment. The expression of cyclinB1, a marker of the G2/M phase, was significantly increased, together with increased Bim expression and decreased Bcl-xL expression in apcin-treated Z138 cells. Conclusions CDC20 might contribute to tumorigenesis in MCL. Further studies should be carried out to determine whether CDC20 inhibitors could impede tumor progression in MCL patients. This work was supported by grants from the Natural Science Foundation of Beijing Municipality [7182178]. Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with poor prognosis and high recurrence rates in patients. The development of MCL is largely attributed to cell cycle dysregulation. Cell division cycle 20 (CDC20) is a key member of cell cycle checkpoints, and high expression of CDC20 was reported in a variety of tumors. Few studies have explored the role of CDC20 in MCL. This study was aimed to investigate whether CDC20 could promote cancer progression and the potential of CDC20 to be a therapeutic target in MCL. Peripheral blood mononuclear cells (PBMCs) from 18 MCL patients and 7 healthy donors and 5 MCL cell lines (Jeko, Mino, Rec1, Z138, and JVM2) were acquired to detect CDC20 expression. CDC20 inhibitor apcin was used in Z138 to evaluate its antitumor effects in vitro, including cell viability, cell apoptosis, cell cycle, cell migration, and invasion. Possible changes of some related genes were assessed after apcin treatment. CDC20 was overexpressed in 94.4% (17/18) of MCL patients and 5 MCL cell lines compared with healthy controls. Cell growth was inhibited, and cell apoptosis was induced in apcin-treated Z138 cells. After 48 h apcin treatment, cell cycle was arrested in the G2/M phase, characterized by an increased number of Z138 cells in this period. The abilities of cell migration and invasion were significantly attenuated with apcin treatment. The expression of cyclinB1, a marker of the G2/M phase, was significantly increased, together with increased Bim expression and decreased Bcl-xL expression in apcin-treated Z138 cells. CDC20 might contribute to tumorigenesis in MCL. Further studies should be carried out to determine whether CDC20 inhibitors could impede tumor progression in MCL patients. This work was supported by grants from the Natural Science Foundation of Beijing Municipality [7182178].

Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer

Homozygous Variants in CDC23 Cause Female Infertility Characterized by Oocyte Maturation Defects.

Novel Mutations in CDC20 Are Associated with Female Infertility Due to Oocyte Maturation Abnormality and Early Embryonic Arrest

Loss of Spindle Assembly Checkpoint–mediated Inhibition of Cdc20 Promotes Tumorigenesis in Mice

Identification of Novel Mutations in CDC20: Expanding the Mutational Spectrum for Female Infertility

Abstract 1640: The role of CDC20 in the progression of colorectal cancer

Abstract PR09: Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene

Abstract 3012: Characterizing the functional significance of "variant of uncertain significance" of the tumour suppressor CDH1

A Novel CDC42 Variant with Impaired Thymopoiesis, IL-7R Signaling, PAK1 Binding, and TCR Repertoire Diversity

Patterns and Functional Implications of Rare Germline Variants Across 12 Cancer Types.

Cdc20 Is Critical for Meiosis I and Fertility of Female Mice

Abstract 6155: Germline variants in cancer susceptibility genes and subsequent neoplasm risks after childhood cancer: A pooled analysis of two large-scale cohorts

Prevalence and Spectrum Analysis of Germline DICER1 Variants of Solid Tumors: Decoding the Mysterious Signals of the Genome.

A second hotspot for pathogenic exon-skipping variants in CDC45

Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

Identification of a Novel Mutation in CTCF in a Family with MRD21

Abstract 3438: Integrated Analysis of Germline and Somatic Variants in Renal Clear Cell Carcinoma

Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency

MCL-363: Overexpression of CDC20 Promotes Cancer Progression in Mantle Cell Lymphoma

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.

Rare Germline Variants in Known Melanoma Susceptibility Genes in Familial Melanoma